Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Current guidelines recommend temozolomide as the first-line chemotherapy for aggressive pituitary neuroendocrine tumours. However, no clinical trials have been conducted to date and clinical experience is quite limited. We retrospectively analyzed 28 patients (9 women and 19 men), aged 46.6 + 16.9,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamas, Cristina, Cámara, Rosa, Fajardo, Carmen, Remon-Ruiz, Pablo, Biagetti, Betina, Guerrero-Pérez, Fernando, Araujo-Castro, Marta, Mora, Mireia, Hanzu, Felicia, Iglesias, Pedro, García-Centeno, Rogelio, Soto, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500829/
https://www.ncbi.nlm.nih.gov/pubmed/37720528
http://dx.doi.org/10.3389/fendo.2023.1204206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500829/
https://www.ncbi.nlm.nih.gov/pubmed/37720528
http://dx.doi.org/10.3389/fendo.2023.1204206

Ejemplares similares